FMC Slashes Preliminary Q3 2026 Outlook as Channel Inventory Overhang Forces Guidance Reset

FMC Corporation has issued a preliminary third-quarter 2026 estimate that falls sharply short of the guidance it gave investors just months earlier, according to a report from Newsquawk. The outlet said the agrochemical maker now expects third-quarter revenue of $65 million to $125 million and an adjusted EBITDA loss of as much as $565 million, versus a prior Wall Street view near $868 million cited by the outlet. The news sent FMC shares sharply lower, with Yahoo Finance data showing the stock down 32.82% intraday to $5.44.

A Dramatic Reversal From July Guidance

The new estimate replaces guidance FMC issued on July 29, 2026, when the company told investors to expect third-quarter revenue, excluding its India business, of $840 million to $900 million and adjusted EBITDA of $120 million to $140 million, according to stocktitan.net. Comparing the midpoints of those ranges as our own calculation ($870 million revenue and $130 million adjusted EBITDA) with the preliminary figures reported by Newsquawk shows the scale of the reversal: against the $95 million midpoint of the new $65 million to $125 million revenue range, the implied shortfall is roughly $775 million, or about 89% of the guided midpoint, while a move from $130 million of guided EBITDA to a loss of as much as $565 million would represent a swing of about $695 million at the worst end of the newly disclosed range.

That July update had itself framed the quarter as a timing issue rather than a demand problem. Stocktitan reported FMC's explanation that North American distributors were shifting orders from the third quarter into the fourth to better align purchases with application timing, and that the company expected a return to year-over-year growth in the fourth quarter. The subsequent collapse in the preliminary figures suggests that explanation did not hold.

Commercial Actions and a Channel Inventory Problem

Newsquawk reported that the preliminary figures include an estimated $625 million to $675 million impact tied to commercial actions: lowering prices on select products already sitting with channel customers in key markets and overhauling FMC's selling and pricing model in the United States. Subtracting the $650 million midpoint of that range from the $130 million adjusted EBITDA guidance midpoint ($130 million minus $650 million) implies a loss of roughly $520 million. On our reading, that would account for most, but not all, of the disclosed loss of up to $565 million, with other factors not detailed in the reporting potentially making up the difference.

Chairman, CEO and President Pierre Brondeau, as cited by Newsquawk, attributed the shortfall to weaker-than-expected demand and elevated levels of higher-priced FMC inventory held by certain channel customers, which he said are limiting product movement and replenishment orders. Brondeau added that the company had tried to address the issue incrementally over several prior quarters but concluded that more comprehensive action was now required.

The move fits a broader pattern at FMC. In its second-quarter 2026 results, the company reported volumes down 10% on lower diamide partner orders and weaker demand for core legacy products, particularly in North America, alongside a 7% price decline tied to legacy product pressure and planned Rynaxypyr active pricing actions, per stocktitan.net. Separately, FMC has said its manufacturing redesign is intended to exit high-cost active ingredient and formulation plants and shift production to lower-cost sources so its non-diamide core products can compete better against generics, according to a prnewswire.com release.

Lender Talks and a Leverage Backdrop

Alongside the price cuts and the new U.S. commercial model, FMC has opened discussions with lenders seeking additional covenant flexibility, Yahoo Finance reported, with fuller details expected when the company reports full third-quarter results on October 29. That request follows an earlier period in which, according to a financialmodelingprep.com note describing an earlier dividend cut and outlook downgrade, Mizuho Securities had set a $24 price target against a then-share price of $13.89, implying about 72.79% upside, while citing FMC's net debt to EBITDA ratio at 20.6. That note predates the current preliminary disclosure and the stock's subsequent decline to roughly $5.44, so it should be read as a snapshot from an earlier stage of the company's difficulties rather than a current analyst view on this specific guidance cut.

There is also precedent for large one-off commercial charges at FMC. In the third quarter of 2025, product returns and pricing changes in its India business produced a $282 million charge within approximately $510 million of total write-downs, including $419 million of negative revenue charges, a $144 million credit to cost of sales and $7 million of selling, general and administrative charges, according to the prnewswire.com release. That history suggests FMC has used similarly sized one-time commercial resets before, though the current action is centered on channel pricing and inventory rather than a business held for sale.

Bottom Line

FMC's preliminary numbers describe a quarter that bears little resemblance to the guidance issued in July, with the shortfall concentrated in price cuts aimed at clearing high-cost inventory sitting with channel customers and a parallel overhaul of its U.S. selling model. The company has also opened covenant discussions with lenders, a detail that, alongside any update to full-year guidance, is expected to be addressed more fully at the October 29 earnings report. Until then, the scale of the swing from roughly $130 million of expected EBITDA to a potential loss of up to $565 million leaves significant questions about demand, channel health and balance sheet flexibility unresolved.